Minireview: Not picking pockets: Nuclear receptor alternate-site modulators (NRAMs)

Molecular Endocrinology

Volumn 24, Issue 4, 2010, Pages 683-695

  Moore, Terry W ^a   Mayne, Christopher G ^a   Katzenellenbogen, John A ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ( 4 HEXYLPHENYL)PROP 2 EN 1 ONE; 16ALPHA CYANOPREGNENOLONE; 2,2' DITHIOBISBENZAMIDE; AMIDINOHYDRAZONE; ANDROGEN RECEPTOR; AROMATASE INHIBITOR; BENZAMIDE DERIVATIVE; BROMETHOL; CELL NUCLEUS RECEPTOR; COUMESTROL; DNA; DNA BINDING PROTEIN; ERI 05; ESTROGEN RECEPTOR; HYDROXYFLUTAMIDE; HYDROXYTAMOXIFEN; KETOCONAZOLE; KETONE DERIVATIVE; LEFLUNOMIDE; LIGAND; NUCLEAR RECEPTOR ALTERNATE SITE MODULATOR; NUCLEAR RECEPTOR COREPRESSOR; PACLITAXEL; PREGNANE X RECEPTOR; RECEPTOR BLOCKING AGENT; RIFAMPICIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; THYROID HORMONE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC FINGER PROTEIN;

ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BINDING SITE; BIOSYNTHESIS; CELL PROLIFERATION; DIMERIZATION; DNA RESPONSIVE ELEMENT; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE EXPRESSION; GENE OVEREXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; LIGAND BINDING; MOLECULE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR CELL;

BINDING SITES; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANDROGEN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, ESTROGEN; RECEPTORS, STEROID; RECEPTORS, THYROID HORMONE;

EID: 77950442251     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2009-0362     Document Type: Short Survey

References (117)

1. Jensen EV, Desombre ER, Hurst DJ, Kawashima T, Jungblut PW 1967 Estrogen-receptor interactions in target tissues. Arch Anat Microsc Morphol Exp 56:547-569
2. Jensen EV, Jacobson HI 1962 Basic guides to the mechanism of estrogen action. Recent Prog Horm Res 18:387-414
3. Jensen EV, Suzuki T, Kawashima T, Stumpf WE, Jungblut PW, DeSombre ER 1968 A two-step mechanism for the interaction of estradiol with rat uterus. Proc Natl Acad Sci USA 59:632-638
4. Gronemeyer H, Gustafsson JA, Laudet V 2004 Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 3:950-964
5. Rosenfeld MG, Lunyak VV, Glass CK 2006 Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev 20:1405-1428
6. Wittmann BM, Sherk A, McDonnell DP 2007 Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators. Cancer Res 67:9549-9560
7. Wu YL, Yang X, Ren Z, McDonnell DP, Norris JD, Willson TM, Greene GL 2005 Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol Cell 18:413-424
8. Culig Z, Bartsch G, Hobisch A 2004 Antiandrogens in prostate cancer endocrine therapy. Curr Cancer Drug Targets 4:455-461
9. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN 2007 Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608:1-22
10. Higgins MJ, Stearns V 2009 Understanding resistance to tamoxifen in hormone receptor-positive breast cancer. Clin Chem 55:1453-1455
11. Biswas A, Mani S, Redinbo MR, Krasowski MD, Li H, Ekins S 2009 Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists. Pharm Res 26:1807-1815
12. Kojetin DJ, Burris TP, Jensen EV, Khan SA 2008 Implications of the binding of tamoxifen to the coactivator recognition site of the estrogen receptor. Endocr Relat Cancer 15:851-870
13. Moore TW, Katzenellenbogen JA 2009 Inhibitors of nuclear hormone receptor/coactivator interactions. In: Macor JE, ed. Annual reports in medicinal chemistry. Vol 5. Amsterdam: Academic Press; 443-457
14. Vaz B, Möcklinghoff S, Brunsveld L 2008 Targeting the nuclear receptor-cofactor interaction. In: Ottow E, Weinmann H, eds. Nuclear receptors as drug targets. Weinheim, Germany: Wiley-VCH; 25-45
15. Korn K, Krausz E 2007 Cell-based high-content screening of small-molecule libraries. Curr Opin Chem Biol 11:503-510
16. Niederlein A, Meyenhofer F, White D, BickleM2009 Image analysis in high-content screening. Comb Chem High Throughput Screen 12:899-907
17. Rausch O 2006 High content cellular screening. Curr Opin Chem Biol 10:316-320
18. Brittijn SA, Duivesteijn SJ, Belmamoune M, Bertens LF, Bitter W, de Bruijn JD, Champagne DL, Cuppen E, Flik G, Vandenbroucke-Grauls CM, Janssen RA, de Jong IM, de Kloet ER, Kros A, Meijer AH, Metz JR, van der Sar AM, Schaaf MJ, Schulte-Merker S, Spaink HP, Tak PP, Verbeek FJ, Vervoordeldonk MJ, Vonk FJ, Witte F, et al. 2009 Zebrafish development and regeneration: new tools for biomedical research. Int J Dev Biol 53:835-850
19. Vogt A, Cholewinski A, Shen X, Nelson SG, Lazo JS, Tsang M, Hukriede NA 2009 Automated image-based phenotypic analysis in zebrafish embryos. Dev Dyn 238:656-663
20. Brommage R, Desai U, Revelli JP, Donoviel DB, Fontenot GK, Dacosta CM, Smith DD, Kirkpatrick LL, Coker KJ, Donoviel MS, Eberhart DE, Holt KH, Kelly MR, Paradee WJ, Philips AV, Platt KA, Suwanichkul A, Hansen GM, Sands AT, Zambrowicz BP, Powell DR 2008 High-throughput screening of mouse knockout lines identifies true lean and obese phenotypes. Obesity (Silver Spring) 16:2362-2367
21. Hellrung DJ, Rossi G, Link CJ 2006 High-throughput fluorescent screening of transgenic animals: phenotyping and haplotyping. Cytometry A 69:1092-1095
22. Yeh JR, Munson KM, Elagib KE, Goldfarb AN, Sweetser DA, Peterson RT 2009 Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation. Nat Chem Biol 5:236-243
23. Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris TP, Rastinejad F 2008 Structure of the intact PPAR-γ-RXR-nuclear receptor complex on DNA. Nature 456:350-356
24. Bramlett KS, Wu Y, Burris TP 2001 Ligands specify coactivator nuclear receptor (NR) box affinity for estrogen receptor subtypes. Mol Endocrinol 15:909-922
25. Chang CY, Abdo J, Hartney T, McDonnell DP 2005 Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display. Mol Endocrinol 19:2478-2490
26. Chang C, Norris JD, Grøn H, Paige LA, Hamilton PT, Kenan DJ, Fowlkes D, McDonnell DP 1999 Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors α and β. Mol Cell Biol 19:8226-8239
27. Galande AK, Bramlett KS, Burris TP, Wittliff JL, Spatola AF 2004 Thioether side chain cyclization for helical peptide formation: inhibitors of estrogen receptor-coactivator interactions. J Pept Res 63:297-302
28. Galande AK, Bramlett KS, Trent JO, Burris TP, Wittliff JL, Spatola AF 2005 Potent inhibitors of LXXLL-based protein-protein interactions. Chembiochem 6:1991-1998
29. Galande AK, Spatola AF 2003 Solid-phase synthesis of disulfide heterodimers of peptides. Org Lett 5:3431-3434
30. Geistlinger TR, Guy RK 2001 An inhibitor of the interaction of thyroid hormone receptor β and glucocorticoid interacting protein 1. J Am Chem Soc 123:1525-1526
31. Geistlinger TR, Guy RK 2003 Novel selective inhibitors of the interaction of individual nuclear hormone receptors with a mutually shared steroid receptor coactivator 2. J Am Chem Soc 125:6852-6853
32. Geistlinger TR, Kiplin Guy R 2003 Steroid receptor coactivator peptidomimetics. In: Russell DW, Mangelsdorf DJ, eds. Methods in Enzymology. San Diego: Elsevier; 223-246
33. Geistlinger TR, McReynolds AC, Guy RK 2004 Ligand-selective inhibition of the interaction of steroid receptor coactivators and estrogen receptor isoforms. Chem Biol 11:273-281
34. Hall JM, Chang CY, McDonnell DP 2000 Development of peptide antagonists that target estrogen receptor β-coactivator interactions. Mol Endocrinol 14:2010-2023
35. Heldring N, Pawson T, McDonnell D, Treuter E, Gustafsson JA, Pike ACW 2007 Structural insights into corepressor recognition by antagonist-bound estrogen receptors. J Biol Chem 282:10449-10455
36. Huang HJ, Norris JD, McDonnell DP 2002 Identification of a negative regulatory surface within estrogen receptor α provides evidence in support of a role for compressors in regulating cellular responses to agonists and antagonists. Mol Endocrinol 16:1778-1792
37. Kong EH, Heldring N, Gustafsson JA, Treuter E, Hubbard RE, Pike ACW 2005 Delineation of a unique protein-protein interaction site on the surface of the estrogen receptor. Proc Natl Acad Sci USA 102:3593-3598
38. Leduc AM, Trent JO, Wittliff JL, Bramlett KS, Briggs SL, Chirgadze NY, Wang Y, Burris TP, Spatola AF 2003 Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions. Proc Natl Acad Sci USA 100:11273-11278
39. Mettu NB, Stanley TB, Dwyer MA, Jansen MS, Allen JE, Hall JM, McDonnell DP 2007 The nuclear receptor-coactivator interaction surface as a target for peptide antagonists of the peroxisome proliferator-activated receptors. Mol Endocrinol 21:2361-2377
40. Moore JM, Galicia SJ, McReynolds AC, Nguyen NH, Scanlan TS, Guy RK 2004 Quantitative proteomics of the thyroid hormone receptor-coregulator interactions. J Biol Chem 279:27584-27590
41. Norris JD, Paige LA, Christensen DJ, Chang CY, Huacani MR, Fan D, Hamilton PT, Fowlkes DM, McDonnell DP 1999 Peptide antagonists of the human estrogen receptor. Science 285:744-746
42. Paige LA, Christensen DJ, Grøn H, Norris JD, Gottlin EB, Padilla KM, Chang CY, Ballas LM, Hamilton PT, McDonnell DP, Fowlkes DM 1999 Estrogen receptor (ER) modulators each induce distinct conformational changes in ER α and ER α. Proc Natl Acad Sci USA 96:3999-4004
43. Pike JW, Pathrose P, Barmina O, Chang CY, McDonnell DP, Yamamoto H, Shevde NK 2003 Synthetic LXXLL peptides antagonize 1α25-dihydroxyvitamin D-3-dependent transcription. J Cell Biochem 88:252-258
44. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS 1997 AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965-968
45. Oñate SA, Tsai SY, Tsai MJ, O'Malley BW 1995 Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:1354-1357
46. Chen JD, Evans RM 1995 A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377:454-457
47. Hörlein AJ, Nää r AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamei Y, Söderström M, Glass CK 1995 Ligand-independent repression by the thyroid-hormone receptor-mediated by a nuclear receptor co-repressor. Nature 377:397-404
48. Brown M, Sharp PA 1990 Human estrogen receptor forms multiple protein-DNA complexes. J Biol Chem 265:11238-11243
49. Lonard DM, Lanz RB, O'Malley BW 2007 Nuclear receptor co-regulators and human disease. Endocr Rev 28:575-587
50. Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, McKenna NJ, Onate SA, Tsai SY, Tsai MJ, O'Malley BW 1997 Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389:194-198
51. Glass CK, Rosenfeld MG 2000 The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14:121-141
52. Jeyakumar M, Katzenellenbogen JA 2009 A dual-acceptor time-resolved Foster resonance energy transfer assay for simultaneous determination of thyroid hormone regulation of corepressor and coactivator binding to the thyroid hormone receptor: mimicking the cellular context of thyroid hormone action. Anal Biochem 386:73-78
53. Jeyakumar M, Webb P, Baxter JD, Scanlan TS, Katzenellenbogen JA 2008 Quantification of ligand-regulated nuclear receptor core-pressor and coactivator binding, key interactions determining ligand potency and efficacy for the thyroid hormone receptor. Biochemistry 47:7465-7476
54. Nguyen NH, Apriletti JW, Cunha Lima ST, Webb P, Baxter JD, Scanlan TS 2002 Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. J Med Chem 45:3310-3320
55. Rosenfeld MG, Ju BG, Perissi V, Lunyak V, Solum D, Zhu P, Rose D, Glass C 2005 Derepression strategies in regulated gene expression. FASEB J 19:A809 (abstract)
56. Yan J, Yu CT, Ozen M, Ittmann M, Tsai SY, Tsai MJ 2006 Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. Cancer Res 66:11039-11046
57. Lee SK, Kim HJ, Na SY, Kim TS, Choi HS, Im SY, Lee JW 1998 Steroid receptor coactivator-1 coactivates activating protein-1-mediated transactivations through interaction with the c-Jun and c-Fos subunits. J Biol Chem 273:16651-16654
58. Werbajh S, Nojek I, Lanz R, Costas MA 2000 RAC-3 is a NF-κB coactivator. FEBS Lett 485:195-199
59. Arimura A, van Peer M, Schröder AJ, Rothman PB 2004 The transcriptional co-activator p/CIP (NCoA-3) is up-regulated by STAT6 and serves as a positive regulator of transcriptional activation by STAT6. J Biol Chem 279:31105-31112
60. Louie MC, Zou JX, Rabinovich A, Chen HW 2004 ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol Cell Biol 24:5157-5171
61. Chang CY, McDonnell DP 2005 Androgen receptor-cofactor interactions as targets for new drug discovery. Trends Pharmacol Sci 26:225-228
62. Matias PM, Donner P, Coelho R, Thomaz M, Peixoto C, Macedo S, Otto N, Joschko S, Scholz P, Wegg A, Bäsler S, Schäfer M, Egner U, Carrondo MA 2000 Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 275:26164-26171
63. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937
64. Heery DM, Kalkhoven E, Hoare S, Parker MG 1997 A signature motif in transcriptional co-activators mediates binding to nuclear receptor. Nature 387:733-736
65. Mak HY, Hoare S, Henttu PM, Parker MG 1999 Molecular determinants of the estrogen receptor-coactivator interface. Mol Cell Biol 19:3895-3903
66. Feng W, Ribeiro RC, Wagner RL, Nguyen H, Apriletti JW, Fletterick RJ, Baxter JD, Kushner PJ, West BL 1998 Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 280:1747-1749
67. Rodriguez AL, Tamrazi A, Collins ML, Katzenellenbogen JA 2004 Design, synthesis, and in vitro biological evaluation of small molecule inhibitors of estrogen receptor a coactivator binding. J Med Chem 47:600-611
68. Parent AA, Gunther JR, Katzenellenbogen JA 2008 Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding. J Med Chem 51:6512-6530
69. Gunther JR, Du Y, Rhoden E, Lewis I, Revennaugh B, Moore TW, Kim SH, Dingledine R, Fu H, Katzenellenbogen JA 2009 A set of time-resolved fluorescence resonance energy transfer assays for the discovery of inhibitors of estrogen receptor-coactivator binding. J Biomol Screen 14:181-193
70. Gunther JR, Moore TW, Collins ML, Katzenellenbogen JA 2008 Amphipathic benzenes are designed inhibitors of the estrogen receptor α/steroid receptor coactivator interaction. ACS Chem Biol 3:282-286
71. Shao D, Berrodin TJ, Manas E, Hauze D, Powers R, Bapat A, Gonder D, Winneker RC, Frail DE 2004 Identification of novel estrogen receptor [alpha] antagonists. J Steroid Biochem Mol Biol 88:351-360
72. LaFrate AL, Gunther JR, Carlson KE, Katzenellenbogen JA 2008 Synthesis and biological evaluation of guanylhydrazone coactivator binding inhibitors for the estrogen receptor. Bioorg Med Chem 16:10075-10084
73. Wang Y, Chirgadze NY, Briggs SL, Khan S, Jensen EV, Burris TP 2006 A second binding site for hydroxytamoxifen within the coactivator-binding groove of estrogen receptor β. Proc Natl Acad Sci USA 103:9908-9911
74. Hedden A, Müller V, Jensen EV 1995 A new interpretation of antiestrogen action. Ann NY Acad Sci 761:109-120
75. Martin PM, Berthois Y, Jensen EV 1988 Binding of antiestrogens exposes an occult antigenic determinant in the human estrogen receptor. Proc Natl Acad Sci USA 85:2533-2537
76. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engström O, Ohman L, Greene GL, Gustafsson JA, Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-758
77. Carraz M, Zwart W, Phan T, Michalides R, Brunsveld L 2009 Perturbation of estrogen receptor α localization with synthetic nona-arginine LXXLL-peptide coactivator binding inhibitors. Chem Biol 16:702-711
78. Tünnemann G, Martin RM, Haupt S, Patsch C, Edenhofer F, Cardoso MC 2006 Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. FASEB J 20:1775-1784
79. Becerril J, Hamilton AD 2007 Helix mimetics as inhibitors of the interaction of the estrogen receptor with coactivator peptides. Angew Chem Int Ed Engl 46:4471-4473
80. Zhou HB, Collins ML, Gunther JR, Comninos JS, Katzenellenbogen JA 2007 Bicyclo[2.2.2]octanes: close structural mimics of the nuclear receptor-binding motif of steroid receptor coactivators. Bioorg Med Chem Lett 17:4118-4122
81. Arnold LA, Estébanez-Perpiñá E, Togashi M, Jouravel N, Shelat A, McReynolds AC, Mar E, Nguyen P, Baxter JD, Fletterick RJ, Webb P, Guy RK 2005 Discovery of small molecule inhibitors of the interaction of the thyroid hormone receptor with transcriptional coregulators. J Biol Chem 280:43048-43055
82. Estébanez-Perpiñá E, Arnold LA, Jouravel N, Togashi M, Blethrow J, Mar E, Nguyen P, Phillips KJ, Baxter JD, Webb P, Guy RK, Fletterick RJ 2007 Structural insight into the mode of action of a direct inhibitor of coregulator binding to the thyroid hormone receptor. Mol Endocrinol 21:2919-2928
83. Katzenellenbogen JA, Carlson KE, Heiman DF, Robertson DW, Wei LL, Katzenellenbogen BS 1983 Efficient and highly selective covalent labeling of the estrogen receptor with [3H]tamoxifen aziridine. J Biol Chem 258:3487-3495
84. Arnold LA, Kosinski A, Estébanez-Perpiñá E, Fletterick RJ, Guy RK 2007 Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem 50:5269-5280
85. Hwang JY, Arnold LA, Zhu F, Kosinski A, Mangano TJ, Setola V, Roth BL, Guy RK 2009 Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem 52:3892-3901
86. Wells JA, McClendon CL 2007 Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450:1001-1009
87. Hur E, Pfaff SJ, Payne ES, Grøn H, Buehrer BM, Fletterick RJ 2004 Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biol 2:E274
88. Gunther JR, Parent AA, Katzenellenbogen JA 2009 Alternative inhibition of androgen receptor signaling: peptidomimetic pyrimidines as direct androgen receptor/coactivator disruptors. ACS Chem Biol 4:435-440
89. Chen Y, Sawyers CL, Scher HI 2008 Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 8:440-448
90. Taplin ME 2007 Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 4:236-244
91. Takeshita A, Taguchi M, Koibuchi N, Ozawa Y 2002 Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition by xenobiotics. J Biol Chem 277:32453-32458
92. Huang H, Wang H, Sinz M, Zoeckler M, Staudinger J, Redinbo MR, Teotico DG, Locker J, Kalpana GV, Mani S 2007 Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 26:258-268
93. Das BC, Madhukumar AV, Anguiano J, Kim S, Sinz M, Zvyaga TA, Power EC, Ganellin CR, Mani S 2008 Synthesis of novel ketoconazole derivatives as inhibitors of the human pregnane X receptor (PXR; NR1I2; also termed SXR, PAR). Bioorg Med Chem Lett 18:3974-3977
94. Ekins S, Chang C, Mani S, Krasowski MD, Reschly EJ, Iyer M, Kholodovych V, Ai N, Welsh WJ, Sinz M, Swaan PW, Patel R, Bachmann K 2007 Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol Pharmacol 72:592-603
95. Ekins S, Kholodovych V, Ai N, Sinz M, Gal J, Gera L, Welsh WJ, Bachmann K, Mani S 2008 Computational discovery of novel low micromolar human pregnane X receptor antagonists. Mol Pharmacol 74:662-672
96. Wang H, Li H, Moore LB, Johnson MD, Maglich JM, Goodwin B, Ittoop OR, Wisely B, Creech K, Parks DJ, Collins JL, Willson TM, Kalpana GV, Venkatesh M, Xie W, Cho SY, Roboz J, Redinbo M, Moore JT, Mani S 2008 The phytoestrogen Coumestrol is a naturally occurring antagonist of the human pregnane X receptor. Mol Endocrinol 22:838-857
97. Cos P, De Bruyne T, Apers S, Vanden Berghe D, Pieters L, Vlietinck AJ 2003 Phytoestrogens: recent developments. Planta Med 69:589-599
98. Estébanez-Perpiñá E, Arnold AA, Nguyen P, Rodrigues ED, Mar E, Bateman R, Pallai P, Shokat KM, Baxter JD, Guy RK, Webb P, Fletterick RJ 2007 A surface on the androgen receptor that allosterically regulates coactivator binding. Proc Natl Acad Sci USA 104:16074-16079
99. Feau C, Arnold LA, Kosinski A, Zhu F, Connelly M, Guy RK 2009 Novel flufenamic acid analogs as inhibitors of androgen receptor mediated transcription. ACS Chem Biol 4:834-843
100. Roche PJ, Hoare SA, ParkerMG1992 A consensus DNA-binding site for the androgen receptor. Mol Endocrinol 6:2229-2235
101. Klein-Hitpass L, Tsai SY, Greene GL, Clark JH, Tsai MJ, O'Malley BW 1989 Specific binding of estrogen-receptor to the estrogen response element. Mol Cell Biol 9:43-49
102. Schwabe JW, Chapman L, Finch JT, Rhodes D 1993 The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: how receptors discriminate between their response elements. Cell 75:567-578
103. Gearhart MD, Dickinson L, Ehley J, Melander C, Dervan PB, Wright PE, Gottesfeld JM 2005 Inhibition of DNA binding by human estrogen-related receptor 2 and estrogen receptor α with minor groove binding polyamides. Biochemistry (Mosc) 44:4196-4203
104. Dervan PB, Edelson BS 2003 Recognition of the DNA minor groove by pyrrole-imidazole polyamides. Curr Opin Struct Biol 13:284-299
105. Nickols NG, Dervan PB 2007 Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proc Natl Acad Sci USA 104:10418-10423
106. Chenoweth DM, Harki DA, Phillips JW, Dose C, Dervan PB 2009 Cyclic pyrrole-imidazole polyamides targeted to the androgen response element. J Am Chem Soc 131:7182-7188
107. Wang LH, Yang XY, Zhang X, An P, Kim HJ, Huang J, Clarke R, Osborne CK, Inman JK, Appella E, Farrar WL 2006 Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell 10:487-499
108. Huang M, Maynard A, Turpin JA, Graham L, Janini GM, Covell DG, Rice WG 1998 Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins. J Med Chem 41:1371-1381
109. Kim HJ, Kim JY, Meng Z, Wang LH, Liu F, Conrads TP, Burke TR, Veenstra TD, Farrar WL 2007 15-deoxy-[Delta]12,14-prostaglandin J2 inhibits transcriptional activity of estrogen receptor-α via covalent modification of DNA-binding domain. Cancer Res 67:2595-2602
110. Mao C, PattersonNM,Cherian MT, Aninye IO, Zhang C, Montoya JB, Cheng J, Putt KS, Hergenrother PJ, Wilson EM, Nardulli AM, Nordeen SK, Shapiro DJ 2008 A new small molecule inhibitor of estrogen receptor α binding to estrogen response elements blocks estrogen-dependent growth of cancer cells. J Biol Chem 283:12819-12830
111. Jones JO, Bolton EC, Huang Y, Feau C, Guy RK, Yamamoto KR, Hann B, Diamond MI 2009 Non-competitive androgen receptor inhibition in vitro and in vivo. Proc Natl Acad Sci USA 106:7233-7238
112. Jones JO, Diamond MI 2008 A cellular conformation-based screen for androgen receptor inhibitors. ACS Chem Biol 3:412-418
113. Jones JO, An WF, Diamond MI 2009 AR inhibitors identified by high-throughput microscopy detection of conformational change and subcellular localization. ACS Chem Biol 4:199-208
114. Nishimura K, Ting HJ, Harada Y, Tokizane T, Nonomura N, Kang HY, Chang HC, Yeh S, Miyamoto H, Shin M, Aozasa K, Okuyama A, Chang C 2003 Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator. Cancer Res 63:4888-4894
115. Joseph JD, Wittmann BM, Dwyer MA, Cui H, Dye DA, McDonnell DP, Norris JD 2009 Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists. Proc Natl Acad Sci USA 106:12178-12183
116. Norris JD, Joseph JD, Sherk AB, Juzumiene D, Turnbull PS, Rafferty SW, Cui H, Anderson E, Fan D, Dye DA, Deng X, Kazmin D, Chang CY, Willson TM, McDonnell DP 2009 Differential presentation of protein interaction surfaces on the androgen receptor defines the pharmacological actions of bound ligands. Chem Biol 16:452-460
117. Yudt MR, Koide S 2001 Preventing estrogen receptor action with dimer-interface peptides. Steroids 66:549-558